CION Ameerpet
Immunotherapy Cost & Access · Patient Assistance in India
Patient Assistance Programmes — How They Work and How to Apply
For most Indian families the blocking question is not whether immunotherapy might help — it is whether the money exists at all. Assistance runs through five separate routes, each with its own test, its own paperwork and its own deadline. This page sets out what exists, who qualifies, and what actually happens after you apply. Scheme and regulatory references follow CDSCO and the published rules of each scheme.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- Five routes, not one — Manufacturer dose support, income-tested access, government schemes, relief-fund grants and sponsor-supplied trial drug all work differently.
- Dose support is the biggest lever — A programme that supplies a share of cycles at no charge cuts the drug line by that share, without changing the treatment plan.
- Apply before cycle one — Almost every route is decided on documents, and retrospective claims are far harder to get through than pre-treatment ones.
- No guarantee of cover, anywhere — Programme ratios, scheme ceilings and empanelment all change. Only a written confirmation for your case, dated, counts.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
What exists
What Patient Assistance Programmes Exist for Immunotherapy in India?
Five routes exist, and they are not alternatives to each other. Manufacturer dose-support programmes supply a share of cycles at no charge. Income-tested access programmes reduce the price. Government schemes pay up to a package ceiling. Relief funds and charitable trusts give one-time grants. Clinical trial sponsors supply the drug themselves.
| Route | What it typically does | Who runs it | Where you apply |
|---|---|---|---|
| Manufacturer dose support — the “buy some, get some” model | Supplies a defined number of cycles at no charge once a defined number have been purchased, up to a programme ceiling | The company that makes the drug, usually through an India programme partner | Through the treating oncologist and the hospital pharmacy, before cycle one wherever possible |
| Income-tested manufacturer access programme | Reduces the price per cycle, or supplies the drug at no charge, for households below a stated income threshold | Manufacturer, often via a third-party administrator or a partner NGO | Same route — the oncologist certifies the prescription, the family submits income proof |
| Government health schemes — Aarogyasri, Ayushman Bharat PM-JAY, CGHS, ECHS, ESI | Pay for a listed package up to a fixed ceiling. High-cost immunotherapy commonly sits above that ceiling, so cover is often partial | State or central government | The empanelled hospital’s scheme desk, which raises pre-authorisation before the cycle |
| Relief funds and charitable trusts | A one-time grant against a specific itemised estimate. It does not repeat automatically for later cycles | Central and state relief funds, hospital trusts, registered charities | District collectorate or hospital medical social worker, with an official recommendation |
| Clinical trial with sponsor-supplied drug | The investigational drug, and often the protocol-required tests, are provided by the sponsor at the trial site | The trial sponsor | Only through a site running that trial, and only if the eligibility criteria are met |
Programme ratios, income thresholds, package lists and ceilings all change, and a programme can be withdrawn or paused. Nothing here is a confirmation that a route is open to you. Ask for the current position in writing, dated, for your diagnosis and your centre — that is the only version that can be planned around. All descriptions on this page are indicative, as of August 2026.
Did you know?
The “buy some, get some” model changes the cost of the whole course, not of one bill. On three-weekly dosing a year of treatment is roughly seventeen cycles — so a programme that supplies one cycle at no charge for every two purchased removes about a third of the drug cost across the cycles it covers. Every programme sets its own ratio and its own ceiling, so the arithmetic has to be done for the specific offer in front of you. Indicative, as of August 2026.
Eligibility
Who Qualifies for a Patient Assistance Programme?
Qualification is decided on documents, not on need. Most routes require a confirmed histopathology or biomarker report, a written prescription from the treating oncologist for an approved indication, and proof of identity and residence. Income-tested routes add an income certificate. Government schemes add a scheme card and treatment at an empanelled hospital.
| What is checked | Manufacturer dose support | Income-tested access | Government scheme | Relief fund or trust |
|---|---|---|---|---|
| Confirmed diagnosis on paper | Required | Required | Required | Required |
| Prescription for an approved indication | Required | Required | Required, and within the listed package | Required |
| Household income test | Usually not applied | Yes — this is the core test | Applied in some schemes, via ration-card category | Yes |
| Where you are treated | Any centre the programme recognises | Any centre the programme recognises | Empanelled hospital only | Usually the hospital named in the sanction letter |
| Timing of the application | Strongly preferred before cycle one | Usually mandatory before cycle one | Mandatory — pre-authorisation precedes the cycle | Preferred before; retrospective claims are harder |
| Does it repeat for later cycles? | Yes, up to the programme ceiling | Yes, subject to re-verification | Yes, up to the package ceiling | No — a one-time grant |
Documents worth assembling before you ask anyone anything:
- Histopathology report — the signed original, plus any immunohistochemistry or biomarker report the prescription depends on.
- The oncologist’s written prescription — naming the treatment, the dose basis and the planned number of cycles.
- An itemised hospital estimate — drug separated from administration, tests and scans. A single lump-sum figure is rejected by most funds.
- Identity and residence proof — Aadhaar, ration card, and the scheme card if you hold one.
- A current income certificate — issued for the correct household, in date. This is the single most common reason an income-tested file stalls.
- Existing insurance details — some programmes ask what a policy has already paid before deciding what they will add.
Being eligible at the start is not the same as being supported for the whole course. Most programmes cap the number of cycles they will cover, and most schemes cap the rupee amount. Ask what the ceiling is on the day you apply, and ask what happens at the cycle after it is reached.
What it actually changes
How Much Difference Does a Patient Assistance Programme Actually Make?
It depends on the route, and it changes the drug line only. A dose-support programme that supplies one cycle at no charge for every two purchased removes roughly a third of the drug cost. A government package ceiling caps what the scheme pays, not what the treatment costs. Administration, tests and scans are unaffected.
| Line on the bill | What assistance does to it |
|---|---|
| The drug itself — the largest single line | Reduced directly, in proportion to the ratio, discount or ceiling the programme sets. This is where every route does its work. |
| Day-care administration | Unchanged. Chair time, nursing, the IV set, pre-medication and the observation period are billed as usual. |
| Pre-cycle blood tests | Unchanged. Counts, liver, kidney and thyroid checks are repeated before each cycle. |
| Response-assessment scans, roughly every 8–12 weeks | Unchanged. Response-assessment PET-CT is coordinated at partner imaging centres rather than owned by CION, and is billed by them. |
| Treating an immune-related side effect | Unchanged, and not usually covered by any drug programme. Steroids, extra consultations or an admission are billed separately. |
| Travel, stay and attendant costs | Unchanged. On a two-year schedule these add up to a real number that no programme addresses. |
All of this is indicative, as of August 2026. This page deliberately quotes no price against any named molecule or brand — programme terms differ by product and change without notice, and a figure copied off a page is not an estimate. Ask the treating centre for an itemised, dated estimate for your own prescription.
Two levers families reach for, and only one of them is safe to pull alone. Applying for assistance changes what you pay without changing the treatment. Shortening or stretching the course changes the treatment itself, and that is a clinical decision for your oncologist, not a purchasing one — the trade-offs are set out in Can You Take Fewer Cycles to Reduce Cost?
Assistance is not cover. Nothing on this page promises that any programme, scheme or fund will pay for your treatment. Ratios, ceilings, empanelment and eligibility rules all change, and a decision on one patient’s file says nothing about the next. Get the position confirmed in writing for your case, with a date on it, before cycle one.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Find Out What You Would Actually Pay
A free consultation includes an indicative, itemised cost plan and a plain walk-through of the assistance routes that could apply to your case.
The application
How Do You Apply, and How Long Does It Take?
Start at the treating hospital, not with the manufacturer. Your oncologist writes the prescription and certifies the indication; the hospital pharmacy or scheme desk submits the file. A manufacturer dose-support file is usually decided in about one to three weeks. Government pre-authorisation is often faster. A relief-fund sanction can take several weeks.
-
Ask the question at the first consultation
Say plainly that cost is a constraint. It is a legitimate clinical input, not an embarrassment, and it changes what your oncologist puts in front of you. Asking after cycle one closes off the routes that require a pre-treatment application.
-
Get the prescription and the indication in writing
Every route is checked against the approved indication for the prescribed treatment. If the prescription and the histopathology report do not match on paper, the file stops there, whatever the household circumstances are.
-
Ask the hospital pharmacy which programmes currently apply
The pharmacy and the scheme desk know which programmes are live this month for the product prescribed. That is a current-status question, not something to research from a web page — programme terms move.
-
Submit one complete file rather than three partial ones
Most delays are documentary. An out-of-date income certificate, an unsigned prescription or a lump-sum estimate with no breakdown will each send the file back to the start of the queue.
-
Get the decision, and the ceiling, in writing
A verbal approval is not something you can budget against. Ask for the sanctioned amount or cycle count, the validity period, and what the process is when the ceiling is reached.
-
Re-check before every scan and every re-authorisation
Support is granted in blocks, not once. Diarise the re-verification date. Treatment being interrupted because paperwork lapsed is avoidable and, in practice, common.
| Route | Who submits the file | Typical time to a decision (Aug 2026) | What usually holds it up |
|---|---|---|---|
| Manufacturer dose support | Hospital pharmacy, with the oncologist’s certification | About 1–3 weeks from a complete file | Missing histopathology, unsigned prescription, or a mismatch with the approved indication |
| Income-tested access programme | The family, with the oncologist and a programme administrator | About 2–4 weeks | Income certificate out of date, or issued for the wrong household |
| Government scheme pre-authorisation | The empanelled hospital’s scheme desk | Often within a few working days | Package not listed, hospital not empanelled, or card details that do not match |
| Relief fund or charitable trust | The family, with a hospital estimate and the medical social worker | Several weeks, sometimes longer | Estimate not itemised, missing official recommendation, incomplete income proof |
| Clinical trial screening | The trial site study team | Screening usually takes 1–3 weeks | Not meeting the eligibility criteria — a clinical matter, not a paperwork one |
These are typical timelines observed in practice, indicative as of August 2026 — they are not commitments, and no route has a guaranteed turnaround. Plan the first cycle date around the slowest file you are depending on, and tell your oncologist if a delay is going to push treatment back, so the clinical risk of waiting is weighed rather than assumed.
What goes wrong
Why Do Patient Assistance Applications Get Rejected?
Most rejections are documentary, not financial. The commonest causes are an indication that does not match the approved use, an income certificate that is out of date or in the wrong name, an estimate submitted as one lump sum, treatment started before the file was raised, and an application made at a hospital that is not empanelled.
- The indication does not match — the prescription is for a use the product is not approved for, so the programme cannot support it, however appropriate the treatment may be clinically.
- The income certificate is stale or in the wrong name — most authorities issue these with a validity period, and programmes check the household, not the individual.
- The estimate is a single number — funds sanction against an itemised estimate. Drug, administration, tests and scans have to be shown as separate lines.
- Treatment started first — retrospective claims are the hardest category on every route, and some programmes will not consider them at all.
- The hospital is not empanelled for the scheme — government cover is tied to the centre as much as to the patient, and cannot be transferred after the fact.
- The programme ceiling was already reached — not a rejection of the patient, but the practical effect on the bill is the same, so it needs a plan before it happens.
A rejection is not always final. A file returned for a documentary reason can usually be resubmitted once the document is corrected, and the hospital medical social worker does this routinely. Ask for the reason in writing rather than accepting a verbal “not approved” — the reason is what tells you whether there is anything to fix.
What none of this covers is the rest of the bill. Attendant travel, accommodation near the centre, days of work lost, supportive medicines at home and the cost of managing a side effect are all outside every programme described here. They are set out in The Hidden Costs of Immunotherapy Nobody Budgets For.
Before you decide
Money Should Not Be the Reason a Question Goes Unasked
Tell us where the cost is blocking you. We will be straight about what assistance can and cannot change, and about what the treatment will still cost after it.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Patient Assistance Programmes: Your Questions Answered
What patient assistance programmes exist for immunotherapy in India?
Five routes exist and they are not alternatives to each other. Manufacturer dose-support programmes supply a defined number of cycles at no charge once a defined number have been purchased. Income-tested manufacturer access programmes reduce the price for households below a stated threshold. Government schemes such as Aarogyasri, Ayushman Bharat PM-JAY, CGHS, ECHS and ESI pay for a listed package up to a fixed ceiling. Relief funds and charitable trusts give a one-time grant against an itemised estimate. Clinical trial sponsors supply the investigational drug themselves at the trial site. Families commonly end up combining two or three of these. None of them is a guarantee of cover, and every one of them can change without notice.
Who qualifies for a patient assistance programme?
Qualification is decided on documents, not on need. Every route needs a confirmed diagnosis on paper, usually a histopathology report and any relevant biomarker report, plus a written prescription from the treating oncologist for an approved indication. Income-tested programmes add a current income certificate issued for the correct household. Government schemes add a valid scheme card and treatment at an empanelled hospital, with pre-authorisation raised before the cycle. Relief funds add a recommendation and an itemised hospital estimate. A programme can also apply a ceiling on the number of cycles it will support, so being eligible at the start does not mean support continues for the whole course.
How do I apply for a patient assistance programme, and how long does it take?
Start at the treating hospital, not with the manufacturer. Your oncologist writes the prescription and certifies the indication, and the hospital pharmacy or scheme desk submits the file. As of August 2026, a complete manufacturer dose-support file is typically decided in about one to three weeks. Government scheme pre-authorisation at an empanelled hospital is often decided within a few working days. An income-tested access programme usually takes about two to four weeks. A relief-fund or charitable-trust sanction can take several weeks and sometimes longer. These are typical timelines only, not commitments. Apply before the first cycle wherever possible, because retrospective claims are much harder to get through.
How much can a patient assistance programme actually save?
It changes the drug line, and the drug is the largest single item on an immunotherapy bill. A dose-support programme that supplies one cycle at no charge for every two purchased removes roughly a third of the drug cost across the supported cycles. An income-tested programme reduces the price per cycle by whatever the programme sets. A government package pays up to its ceiling and no further. What does not change is day-care administration, pre-cycle blood tests, response-assessment scans, supportive medicines, and travel and stay. So the total bill falls by less than the headline on the drug suggests. All figures here are indicative, as of August 2026.
Does Aarogyasri or Ayushman Bharat cover immunotherapy?
Government schemes work on listed packages with fixed ceilings rather than on actual cost. Where an immunotherapy package is listed, the scheme pays up to that ceiling at an empanelled hospital and the family pays anything above it. High-cost checkpoint inhibitor treatment commonly sits above the ceiling, so cover is often partial rather than complete, and for some drugs there may be no listed package at all. Package lists, ceilings and empanelment all change, so nothing on this page should be read as confirmation of your cover. Ask the treating hospital scheme desk to check your card, the current package status and the ceiling in writing before the first cycle.
Can I get immunotherapy free through a clinical trial?
In some trials the sponsor supplies the investigational drug, and sometimes the protocol-required tests, at no cost to you. That is a real route and worth asking about. It is not a funding plan you can rely on. Eligibility criteria are narrow, a suitable trial may not be recruiting for your cancer at the time you need treatment, and enrolment is never assured. A trial is entered for clinical reasons first, with the cost effect as a consequence rather than the purpose. Ask your oncologist whether a trial is clinically appropriate for you, and read our page on the clinical trial route before you plan around it.